Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

1.

WHICH QUALITY OF LIFE MEASURES FIT YOUR RELATIVE EFFECTIVENESS ASSESSMENT?

Cleemput I, Neyt M.

Int J Technol Assess Health Care. 2015 Jun 11:1-7. [Epub ahead of print]

PMID:
26062796
2.

Belgian guidelines for economic evaluations: second edition.

Thiry N, Neyt M, Van De Sande S, Cleemput I.

Int J Technol Assess Health Care. 2014 Dec;30(6):601-7. doi: 10.1017/S0266462314000725.

PMID:
25816826
3.

Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.

Pavlovic M, Teljeur C, Wieseler B, Klemp M, Cleemput I, Neyt M.

Int J Technol Assess Health Care. 2014 Nov;30(5):508-13. doi: 10.1017/S0266462314000592.

PMID:
25747560
4.

Belgian guidelines for budget impact analyses.

Neyt M, Cleemput I, Sande SV, Thiry N.

Acta Clin Belg. 2015 Jun;70(3):175-80. doi: 10.1179/2295333714Y.0000000118. Epub 2015 Jan 11.

PMID:
25579611
5.

The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Vlayen J.

Ann Cardiothorac Surg. 2014 Sep;3(5):439-49. doi: 10.3978/j.issn.2225-319X.2014.09.02. Review.

6.

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

Neyt M, Hulstaert F, Gyselaers W.

BMJ Open. 2014 Nov 7;4(11):e005922. doi: 10.1136/bmjopen-2014-005922.

7.

Search MEDLINE for economic evaluations: tips to translate an OVID strategy into a PubMed one.

Neyt M, Chalon PX.

Pharmacoeconomics. 2013 Dec;31(12):1087-90. doi: 10.1007/s40273-013-0103-0. No abstract available.

PMID:
24202991
8.

Authors' reply to Ward.

Van Brabandt H, Neyt M, Devos C.

BMJ. 2013 Oct 2;347:f5868. doi: 10.1136/bmj.f5868. No abstract available.

PMID:
24088554
9.

The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations.

Neyt M, Van Brabandt H, Devos C.

BMC Cardiovasc Disord. 2013 Sep 26;13:78. doi: 10.1186/1471-2261-13-78. Review.

10.

Caution over use of catheter ablation for atrial fibrillation.

Van Brabandt H, Neyt M, Devos C.

BMJ. 2013 Sep 6;347:f5277. doi: 10.1136/bmj.f5277. No abstract available. Erratum in: BMJ. 2013;347:f5688.

PMID:
24014443
11.

Cost-effectiveness of continuous-flow left ventricular assist devices.

Neyt M, Van den Bruel A, Smit Y, De Jonge N, Erasmus M, Van Dijk D, Vlayen J.

Int J Technol Assess Health Care. 2013 Jul;29(3):254-60. doi: 10.1017/S0266462313000238. Epub 2013 Jun 14.

PMID:
23763844
12.

Health technology assessment on catheter ablation of atrial fibrillation in Belgium.

Van Brabandt H, Neyt M, Devos C.

Europace. 2013 May;15(5):618-9. doi: 10.1093/europace/eut085. No abstract available.

13.

[Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].

Stordeur S, Vinck I, Neyt M, Van Brabandt H, Hulstaert F.

Rev Epidemiol Sante Publique. 2013 Apr;61(2):105-10. doi: 10.1016/j.respe.2012.08.004. Epub 2013 Mar 7. French.

PMID:
23477881
14.

Effectiveness of catheter ablation of atrial fibrillation in Belgian practice: a cohort analysis on administrative data.

Van Brabandt H, Neyt M, Devos C.

Europace. 2013 May;15(5):663-8. doi: 10.1093/europace/eut004. Epub 2013 Feb 6.

15.

TAVI: reveal the truth, the whole truth, and nothing but the truth.

Neyt M, Van Brabandt H.

J Med Econ. 2013;16(5):581-5. doi: 10.3111/13696998.2013.772724. Epub 2013 Feb 12. No abstract available.

PMID:
23368739
16.

Questionable levels of evidence in new atrial fibrillation guidelines?

Van Brabandt H, Neyt M, Devos C.

Europace. 2013 Mar;15(3):461. doi: 10.1093/europace/eus393. Epub 2012 Nov 29. No abstract available.

17.

Pre-market clinical evaluations of innovative high-risk medical devices in Europe.

Hulstaert F, Neyt M, Vinck I, Stordeur S, Huić M, Sauerland S, Kuijpers MR, Abrishami P, Vondeling H, Flamion B, Garattini S, Pavlovic M, van Brabandt H.

Int J Technol Assess Health Care. 2012 Jul;28(3):278-84. doi: 10.1017/S0266462312000335.

PMID:
22980705
18.

Transcatheter aortic valve implantation (TAVI): risky and costly.

Van Brabandt H, Neyt M, Hulstaert F.

BMJ. 2012 Jul 31;345:e4710. doi: 10.1136/bmj.e4710. No abstract available.

PMID:
22849955
19.

Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data.

Neyt M, Cleemput I, Thiry N, De Laet C.

Health Policy. 2012 Jul;106(2):207-10. doi: 10.1016/j.healthpol.2012.04.014. Epub 2012 May 16.

PMID:
22608108
20.

The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator.

Neyt M, Van Den Bruel A.

Eur J Health Econ. 2012 Aug;13(4):379-80. doi: 10.1007/s10198-012-0392-9. No abstract available.

PMID:
22572967
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk